Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CEP-11981 |
Synonyms | |
Therapy Description |
CEP-11981 is a multikinase inhibitor that targets VEGFR1-3 and TIE2, which may inhibit tumor angiogenesis and lead to tumor growth inhibition (PMID: 24982343, PMID: 25152243). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CEP-11981 | ESK981|CEP11981|CEP 11981 | TIE2 Inhibitor 3 VEGFR Inhibitor (Pan) 36 | CEP-11981 is a multikinase inhibitor that targets VEGFR1-3 and TIE2, which may inhibit tumor angiogenesis and lead to tumor growth inhibition (PMID: 24982343, PMID: 25152243). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03456804 | Phase II | CEP-11981 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | Completed | USA | 0 |
NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |
NCT03562507 | Phase II | CEP-11981 CEP-11981 + Nivolumab | Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | Terminated | USA | 0 |